...more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and its spinout Seragon... ...Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc.... ...NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor
Elizabeth S. Eaton, Staff Writer
ORIC-101
Aragon Pharmaceuticals Inc.
Ignyta Inc.
ORIC Pharmaceuticals Inc.
Seragon Pharmaceuticals Inc....
...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc.... ...date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer
Jennie Walters
Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...
...its Genentech Inc. unit acquired Seragon Pharmaceuticals Inc. in 2014. This is the second SERD candidate from Seragon... ...see BioCentury Extra, March 29, 2017 & BioCentury Extra, Jan. 12, 2018) .
Elizabeth S. Eaton
ocrelizumab
Ocrevus
RG6046
RG6047
Genentech Inc.
Seragon Pharmaceuticals Inc.
Roche...
...more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and its spinout Seragon... ...Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc.... ...NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor
Elizabeth S. Eaton, Staff Writer
ORIC-101
Aragon Pharmaceuticals Inc.
Ignyta Inc.
ORIC Pharmaceuticals Inc.
Seragon Pharmaceuticals Inc....
...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc.... ...date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer
Jennie Walters
Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...
...its Genentech Inc. unit acquired Seragon Pharmaceuticals Inc. in 2014. This is the second SERD candidate from Seragon... ...see BioCentury Extra, March 29, 2017 & BioCentury Extra, Jan. 12, 2018) .
Elizabeth S. Eaton
ocrelizumab
Ocrevus
RG6046
RG6047
Genentech Inc.
Seragon Pharmaceuticals Inc.
Roche...